CJC-1295 (No DAC) 20mg — Vial Spec, Reconstitution Math & COA

Overview & High-Yield Vial Specifications (20mg Format)

In laboratory research environments, the cjc-1295 (no dac) 20mg specification represents a bulk lyophilized format intended for high-frequency or multi-subject analytical protocols. Containing 20 milligrams of pure synthetic Modified GRF (1-29) peptide without the Drug Affinity Complex attachment, this high-yield vial size allows automated liquid handlers and research technicians to prepare uniform stock solutions without the inter-vial variability associated with opening multiple smaller units.

While standard institutional inventory often relies on single-study sizes such as 2mg or 5mg vials, larger 20mg mass allocations are typically chosen for high-throughput screening, multi-plate in vitro receptor assays, or extended rodent cohort studies. Please note that while PX1 Research maintains standard production stock of CJC-1295 (No DAC) in standard 2mg and 5mg analytical vials, specialized high-yield 20mg fill sizes and bulk lot allocations are routinely supported via custom enterprise ordering through our PX1 Wholesale Account Portal. Exploring our complete selection within the PX1 Peptide Catalog allows research teams to align vial size directly with their automated dosing and assay infrastructure.

Every batch manufactured for PX1 Research undergoes strict synthesis in USA-based, GMP-compliant facilities. Whether packed in standard 2mg, 5mg, or specialized 20mg mass configurations, each lot is subjected to rigorous mass spectrometry and high-performance liquid chromatography to ensure non-degraded, highly reproducible scientific outcomes.

Molecular Structure and GHRH Receptor Kinetics

CJC-1295 (No DAC), chemically designated as Modified GRF (1-29), is a 29-amino-acid synthetic peptide derived from the active N-terminal domain of native Growth Hormone-Releasing Hormone (GHRH). The natural endogenous GHRH peptide comprises 44 amino acids; however, early biochemical truncation studies established that the biological activity resides within the first 29 residues. Native GRF (1-29) is rapidly cleaved in biological systems by the enzyme dipeptidyl peptidase IV (DPP-IV), which targets the Tyr-Ala bond at positions 1 and 2.

To preserve bioactivity in preclinical models, researchers engineered four specific amino acid substitutions into the sequence: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These modification sites significantly enhance resistance to enzymatic degradation while retaining nanomolar affinity for the GHRH receptor (GHRH-R). Unlike the conjugated CJC-1295 variant featuring the Drug Affinity Complex (which covalently binds endogenous serum albumin to extend half-life to several days), CJC-1295 (No DAC) maintains a short plasma half-life of approximately 30 minutes in animal models.

This absence of albumin-binding mechanics preserves natural pulsatile GH release. When introduced into anterior pituitary cell cultures or in vivo rodent assays, CJC-1295 (No DAC) triggers a rapid, controlled influx of intracellular cAMP via adenylate cyclase activation. This signaling cascade induces episodic exocytosis of growth hormone vesicles without causing prolonged receptor desensitization or disrupting physiological feedback loops governed by somatostatin.

20mg Reconstitution Math & Diluent Protocol

Reconstitution of a high-mass lyophilized cake requires precise calculation to maintain intended target concentrations and prevent saturation issues during solubilization. Because a 20mg cake contains substantial peptide mass, utilizing an adequate volume of sterile diluent—typically 0.9% benzyl alcohol-preserved bacteriostatic water—is essential for complete dissolution. Researchers should utilize our interactive Peptide Reconstitution Calculator to verify custom laboratory volume metrics before mixing.

To calculate working stock concentration ($C$), the mass of the peptide ($m = 20\text{ mg} = 20,000\mu\text{g}$) is divided by the volume of added diluent ($V$ in mL):

• 1.0 mL Addition: $20,000\mu\text{g} / 1.0\text{ mL} = 20,000\mu\text{g/mL}$ ($20\mu\text{g per } \mu\text{L}$). This ultra-concentrated stock is suitable for primary aliquoting into micro-centrifuge tubes for deep-freeze storage. • 2.0 mL Addition: $20,000\mu\text{g} / 2.0\text{ mL} = 10,000\mu\text{g/mL}$ ($10\mu\text{g per } \mu\text{L}$). An ideal concentration for high-volume automated liquid handling systems. • 3.0 mL Addition: $20,000\mu\text{g} / 3.0\text{ mL} = 6,666.67\mu\text{g/mL}$ ($6.67\mu\text{g per } \mu\text{L}$). Provides an accessible volumetric scale when preparing micro-doses for delicate rodent models.

When reconstituting cjc-1295 (no dac) 20mg vials, slowly direct the diluent stream down the interior glass wall of the vial rather than shooting liquid directly onto the lyophilized cake. Allow the cake to gently wet and dissolve over 2–5 minutes. Never shake the vial; gentle swiveling or slow inversion prevents shear-stress degradation and surface denaturation of the delicate peptide chain.

Aliquot Planning, Solubilization & Storage Conditions

Because a 20mg vial yields a high concentration of working solution, leaving the entire volume in a single reconstituted glass vial across multiple freeze-thaw cycles or prolonged refrigeration risks peptide aggregation and hydrolytic degradation. Proper laboratory management mandates a structured aliquot protocol immediately following complete dissolution.

Reconstituted solutions should be divided under sterile laminar flow conditions into single-use micro-aliquots using polypropylene microcentrifuge tubes. Standard working aliquots should be calculated based on daily assay throughput. Unused aliquots designated for long-term storage must be frozen immediately at -20°C or -80°C, where the peptide remains stable for up to 6–12 months. Aliquots reserved for immediate active testing should be kept refrigerated at 2°C to 8°C and evaluated within 14 to 21 days.

Lyophilized CJC-1295 (No DAC) 20mg vials supplied by PX1 Research should be stored at -20°C upon receipt in a dark, moisture-controlled environment. Protect vials from light exposure, as UV radiation accelerates photo-oxidation of susceptible residues within the GHRH sequence. Repeated thermal cycling between sub-zero and room temperatures causes loss of secondary structural integrity and must be strictly avoided.

Analytical Quality Assurance & Certificate of Analysis (COA)

Quantifying the exact purity and identity of high-mass peptide vials is essential for downstream empirical accuracy. PX1 Research enforces rigorous quality assurance standards across all catalog and custom fill sizes. Every lot manufactured undergoes comprehensive analytical verification at an independent, ISO 17025-accredited testing laboratory before being released for distribution.

Researchers can review batch-specific data directly by visiting our centralized Certificate of Analysis (COA) Database. Laboratory documentation for every production lot includes:

1. High-Performance Liquid Chromatography (HPLC): Verifies chemical purity, ensuring that the cjc-1295 (no dac) 20mg batch meets or exceeds our strict $\ge 98\%$ purity benchmark, with zero residual manufacturing byproducts or truncated sequences. 2. Liquid Chromatography-Mass Spectrometry (LC-MS): Confirms the exact molecular weight (3288.7 Da) and sequence integrity of the Modified GRF (1-29) structure. 3. Bacterial Endotoxin Analysis: Conducted via Limulus Amebocyte Lysate (LAL) testing to verify that endotoxin levels remain below $< 0.01\text{ EU/mg}$, preventing confounding inflammatory responses in sensitive cell lines or animal models.

Unlike suppliers relying on sample testing or vendor-supplied certificates, PX1 assigns a unique QR code and lot number directly to every physical vial, establishing absolute batch traceability from USA manufacturing suites to your research bench.

Comparative Analysis: CJC-1295 (No DAC) vs. Related Secretagogues

When establishing research protocols targeting the somatotropic axis, selecting the correct GHRH or GHRP analog is crucial for reproducing specific physiologic signaling cascades. CJC-1295 (No DAC) is frequently compared alongside CJC-1295 with DAC, Sermorelin, and selective ghrelin receptor agonists like Ipamorelin.

While CJC-1295 with DAC utilizes covalent albumin conjugation to extend its half-life to several days (inducing a continuous elevation of basal GH), CJC-1295 (No DAC) exhibits a short 30-minute half-life that accurately replicates natural, episodic pituitary release. Compared to un-modified Sermorelin (GRF 1-29), the four strategic amino acid substitutions in CJC-1295 (No DAC) provide significantly higher resistance to DPP-IV cleavage, yielding greater metabolic stability while preserving physiological pulsatility.

In contrast to GHRH analogs, ghrelin receptor agonists such as Ipamorelin act via an entirely distinct receptor family (GHSR-1a). Preclinical studies routinely evaluate synergistic co-administration protocols—combining a GHRH analog with a GHRP/ghrelin agonist—to observe magnified, dual-pathway growth hormone secretion without elevating cortisol or prolactin.

Preclinical Applications in Tissue Repair & Somatotropic Research

Growth hormone-releasing hormone analogs play a foundational role in preclinical investigation surrounding cell proliferation, extracellular matrix remodeling, and metabolic regulation. In vitro data indicate that elevated growth hormone levels induce secondary secretion of Insulin-like Growth Factor 1 (IGF-1) from hepatocytes and localized peripheral tissues.

Rodent models examining skeletal muscle injury, tendon laceration, and cutaneous wound healing demonstrate that sustained downstream IGF-1 signaling accelerates cellular migration, fibroblast proliferation, and collagen deposition. By utilizing CJC-1295 (No DAC) to stimulate natural pituitary secretion, researchers can investigate tissue repair kinetics under physiological pulsatile conditions, avoiding the receptor down-regulation often observed with continuous recombinant growth hormone administration.

Furthermore, animal studies focusing on age-related metabolic decline evaluate how GHRH analogs influence body composition, lipid oxidation, and bone mineral density. Accessing detailed preclinical papers and mechanism overviews through the PX1 Research Library provides laboratory personnel with additional context regarding experimental designs and somatotropic pathway dynamics.

Sourcing Selection: Deciding Between 2mg, 5mg, and 20mg Fills

Selecting the ideal vial size depends primarily on assay duration, subject cohort size, and liquid handling capabilities. For short-duration in vitro protocols or pilot animal studies involving a small number of subjects, smaller standard vial sizes—such as our standard catalog CJC-1295 (No DAC) 2mg and 5mg vials—are highly recommended. These standard sizes minimize reconstituted storage times and eliminate the need for long-term sub-zero storage of liquid aliquots.

Conversely, institutional laboratories utilizing automated robotic workstations or conducting multi-week longitudinal rodent studies benefit substantially from high-yield 20mg fill formats. Preparing a single large-volume stock reduces inter-assay variance and streamlines concentration controls across extensive testing sets.

Whether your team requires standardized catalog units or customized bulk production fills, PX1 Research provides fully traceable, high-purity research compounds backed by same-day shipping from our CA and AZ facilities, full analytical verification, and dedicated enterprise account support.